HCPCS Level II
J1596
Injection, glycopyrrolate, 0.1 mg
Codes near J1596
These sit next to J1596 in the CMS Level II file. All J codes
- J1576Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
- J1577Injection, immune globulin (qivigy), 100 mg
- J1580Injection, garamycin, gentamicin, up to 80 mg
- J1590Injection, gatifloxacin, 10 mg
- J1595Injection, glatiramer acetate, 20 mg
- J1597Injection, glycopyrrolate (glyrx-pf), 0.1 mg
- J1598Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg
- J1599Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg
- J1600Injection, gold sodium thiomalate, up to 50 mg
- J1602Injection, golimumab, 1 mg, for intravenous use
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00143-9584-10 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 400 |
| 00143-9585-25 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 250 |
| 00143-9586-25 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 100 |
| 00143-9587-25 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 50 |
| 00143-9679-10 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 400 |
| 00143-9680-25 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 250 |
| 00143-9681-25 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 100 |
| 00143-9682-25 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 50 |
| 00404-9775-01 | Glycopyrrolate Injection | Henry Schein Inc. | 2 |
| 00404-9776-05 | Glycopyrrolate Injection | Henry Schein Inc. | 10 |
| 00404-9777-20 | Glycopyrrolate Injection | Henry Schein Inc. | 40 |
| 00404-9782-02 | Glycopyrrolate Injection | Henry Schein Inc. | 4 |
| 00404-9867-01 | Glycopyrrolate Injection | Henry Schein Inc. | 2 |
| 00404-9868-20 | Glycopyrrolate Injection | Henry Schein Inc. | 40 |
| 00404-9869-02 | Glycopyrrolate Injection | Henry Schein Inc. | 4 |
| 00404-9870-05 | Glycopyrrolate Injection | Henry Schein Inc. | 10 |
| 00517-4601-25 | Glycopyrrolate Injection | American Regent, Inc. | 50 |
| 00517-4602-25 | Glycopyrrolate Injection | American Regent, Inc. | 100 |
| 00517-4605-25 | Glycopyrrolate Injection | American Regent, Inc. | 250 |
| 00517-4620-25 | Glycopyrrolate Injection | American Regent, Inc. | 1000 |
| 00641-6212-10 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 20 |
| 00641-6213-10 | Glycopyrrolate Injection | Hikma Pharmaceuticals USA Inc. | 40 |
| 00781-3825-96 | Glycopyrrolate Injection | Sandoz Inc. | 50 |
| 00781-3827-96 | Glycopyrrolate Injection | Sandoz Inc. | 100 |
| 00781-3829-96 | Glycopyrrolate Injection | Sandoz Inc. | 250 |
| 00781-3831-95 | Glycopyrrolate Injection | Sandoz Inc. | 400 |
| 25021-0796-01 | Glycopyrrolate Injection | Sagent Pharmaceuticals | 50 |
| 25021-0796-02 | Glycopyrrolate Injection | Sagent Pharmaceuticals | 100 |
| 25021-0796-05 | Glycopyrrolate Injection | Sagent Pharmaceuticals | 250 |
| 50090-4513-00 | Glycopyrrolate Injection | A-S Medication Solutions | 2 |
| 50090-5226-00 | Glycopyrrolate Injection | A-S Medication Solutions | 50 |
| 51662-1487-01 | Glycopyrrolate Injection | HF Acquisition Co. LLC, DBA HealthFirst | 2 |
| 51662-1487-03 | Glycopyrrolate Injection | HF Acquisition Co. LLC, DBA HealthFirst | 50 |
| 51662-1554-03 | Glycopyrrolate Injection | HF Acquisition Co. LLC, DBA HealthFirst | 100 |
| 51662-1601-01 | Glycopyrrolate Injection | HF Acquisition Co. LLC, DBA HealthFirst | 10 |
| 51662-1601-03 | Glycopyrrolate Injection | HF Acquisition Co. LLC, DBA HealthFirst | 250 |
| 60505-6179-05 | Glycopyrrolate Injection | Apotex Corp | 50 |
| 60505-6180-05 | Glycopyrrolate Injection | Apotex Corp | 100 |
| 60505-6181-05 | Glycopyrrolate Injection | Apotex Corp | 250 |
| 60505-6182-04 | Glycopyrrolate Injection | Apotex Corp | 400 |
| 62332-0607-25 | Glycopyrrolate Injection | Alembic Pharmaceuticals Inc. | 50 |
| 62332-0627-25 | Glycopyrrolate Injection | Alembic Pharmaceuticals Inc. | 100 |
| 62332-0628-25 | Glycopyrrolate Injection | Alembic Pharmaceuticals Inc. | 250 |
| 62332-0629-10 | Glycopyrrolate Injection | Alembic Pharmaceuticals Inc. | 400 |
| 63323-0578-01 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 50 |
| 63323-0578-02 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 100 |
| 63323-0578-05 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 250 |
| 63323-0578-11 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 50 |
| 63323-0578-12 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 100 |
| 65219-0801-01 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 50 |
| 66794-0202-42 | Glycopyrrolate Injection | Piramal Critical Care Inc | 50 |
| 66794-0203-42 | Glycopyrrolate Injection | Piramal Critical Care Inc | 100 |
| 66794-0204-42 | Glycopyrrolate Injection | Piramal Critical Care Inc | 250 |
| 66794-0205-41 | Glycopyrrolate Injection | Piramal Critical Care Inc | 400 |
| 70069-0616-10 | Glycopyrrolate Injection | Somerset Pharma, LLC | 400 |
| 70069-0617-25 | Glycopyrrolate Injection | Somerset Pharma, LLC | 50 |
| 70069-0618-25 | Glycopyrrolate Injection | Somerset Pharma, LLC | 100 |
| 70069-0619-25 | Glycopyrrolate Injection | Somerset Pharma, LLC | 250 |
| 70121-1698-07 | Glycopyrrolate Injection | Amneal Pharmaceuticals, LLC | 20 |
| 70121-1699-07 | Glycopyrrolate Injection | Amneal Pharmaceuticals, LLC | 40 |
| 70700-0165-25 | Glycopyrrolate Injection | Xiromed, LLC | 50 |
| 70700-0166-25 | Glycopyrrolate Injection | Xiromed, LLC | 100 |
| 70700-0167-25 | Glycopyrrolate Injection | Xiromed, LLC | 250 |
| 70700-0168-23 | Glycopyrrolate Injection | Xiromed, LLC | 400 |
| 70700-0902-25 | Glycopyrrolate Injection | Xiromed, LLC | 250 |
| 70700-0903-23 | Glycopyrrolate Injection | Xiromed, LLC | 400 |
| 70860-0781-01 | Glycopyrrolate Injection | Athenex Pharmaceutical Division, LLC | 50 |
| 70860-0781-02 | Glycopyrrolate Injection | Athenex Pharmaceutical Division, LLC | 100 |
| 70860-0781-05 | Glycopyrrolate Injection | Athenex Pharmaceutical Division, LLC | 250 |
| 70860-0781-20 | Glycopyrrolate Injection | Athenex Pharmaceutical Division, LLC | 400 |
| 71288-0414-03 | Glycopyrrolate Injection | Meitheal Pharmaceuticals Inc. | 50 |
| 71288-0414-04 | Glycopyrrolate Injection | Meitheal Pharmaceuticals Inc. | 100 |
| 71288-0414-92 | Glycopyrrolate Injection | Meitheal Pharmaceuticals Inc. | 50 |
| 71288-0414-94 | Glycopyrrolate Injection | Meitheal Pharmaceuticals Inc. | 100 |
| 71288-0415-06 | Glycopyrrolate Injection | Meitheal Pharmaceuticals Inc. | 250 |
| 71288-0415-21 | Glycopyrrolate Injection | Meitheal Pharmaceuticals Inc. | 400 |
| 71288-0415-96 | Glycopyrrolate Injection | Meitheal Pharmaceuticals Inc. | 250 |
| 71839-0123-25 | Glycopyrrolate Injection | BE Pharmaceuticals Inc. | 50 |
| 71839-0124-25 | Glycopyrrolate Injection | BE Pharmaceuticals Inc. | 100 |
| 71839-0125-25 | Glycopyrrolate Injection | BE Pharmaceuticals Inc. | 250 |
| 72572-0225-25 | Glycopyrrolate Injection | Civica, Inc. | 25 |
| 72572-0226-25 | Glycopyrrolate Injection | Civica, Inc. | 50 |
| 76045-0203-10 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 48 |
| 76045-0203-20 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 96 |
| 76045-0206-10 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 48 |
| 76045-0208-20 | Glycopyrrolate Injection | FreseniUS Kabi USA, LLC | 96 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.